Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 2.46709725
Author: Trendlyne DVM scores

Turnaround Potential

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

16.61 -0.29 (-1.72%)

60.64% Gain from 52W Low

668.3K

XNAS Volume

XNAS 21 Sep, 2026 5:30 PM (EDT)

Medium Financial Strength

38.9 / 100

Affordable Valuation

53.5 / 100

Technically Moderately Bullish

66.1 / 100

Turnaround Potential These stocks have average financials with good valuations and momentum, indicating turnaround potential View Similar Embed DVM

1Yr Price target upside is 8%

7 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

60.64% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart

Aurinia Pharma Inc Live Price Chart